<DOC>
	<DOCNO>NCT01253512</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multi-center , multi-national , escalate dose , pilot study compare two dos THR-18 placebo administer patient suffer acute ischemic stroke treat Tissue Plasminogen Activator ( tPA ) . The study hypothesis THR-18 safe well tolerated subject suffer acute ischemic stroke treat Thrombolysis .</brief_summary>
	<brief_title>Study Assess Safety Efficacy THR-18 When Administered Patients Suffering Acute Ischemic Stroke Treated With Tissue Plasminogen Activator ( tPA )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multi-center , multi-national , escalate dose , pilot study compare two dos THR-18 ( 0.25 0.5 mg/kg ) placebo administer patient suffer acute ischemic stroke treat Tissue Plasminogen Activator ( tPA ) . A total 22 subject suffer acute ischemic stroke eligible tPA treatment recruit study . Eligible recruitment patient entry National Institutes Health Stroke Scale ( NIHSS ) score 5-18 clinical syndrome include least 1 follow : language dysfunction , visual field defect neglect ( specifically , least 1 point NIHSS item 3 9 11 ) . Alternatively , patient without least 1 point NIHSS item 3 , 9 11 may enrol routine diffusion-weighted magnetic resonance imaging ( MRI ) compute tomography perfusion scan ( CT ) indicate acute stroke involve cerebral cortex , long overall acute neurological deficit within range 5-18 NIHSS point . Stroke onset defined time patient last know without new clinical deficit . Patients whose symptom start 3 hour presentation eligible study . If stroke start sleep , stroke onset recorded time patient last know normal . Patients recruit obtain informed consent . Female subject childbearing potential ( less 2 year ' postmenopausal surgically sterilize ) urine pregnancy test baseline require use adequate effective birth control measure duration trial . Effective birth control measure include hormonal contraception , barrier method diaphragm , intrauterine device ( IUD ) and/or condom spermicide ( IUD , diaphragm , condoms alone rhythm method consider reliable method ) . Patients randomize receive either 0.25 0.5 mg/kg THR-18 placebo escalate manner . tPA administer 0.9 mg/kg ( 10 % total dose Intra Venous ( IV ) bolus reminder infuse IV 60 minute ) . THR-18 bolus give immediately prior tPA bolus , 60 min infusion THR-18 tPA do parallel .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Male female . 2 . Diagnosis acute ischemic stroke onset less 3 hour prior plan start intravenous Tissue Plasminogen Activator ( tPA ) . 3 . Have suffer acute hemispheric ischemic stroke , define acute , focal , neurological deficit ( ) secondary presume vascular event . 4 . Age 1885 year inclusive . 5 . Able sign inform consent . 1 . Participation another study investigational drug device within 30 day study entry , prior participation present study , plan participation another therapeutic trial , prior final ( day 30 ) assessment trial . 2 . Time interval since stroke onset le 3 hour impossible determine high degree confidence . 3 . Symptoms suggestive subarachnoid hemorrhage , even compute tomography perfusion scan ( CT ) magnetic resonance imaging ( MRI ) scan negative hemorrhage . 4 . Evidence acute myocardial infarction . 5 . Acute Pericarditis 6 . Patients would refuse blood transfusion medically indicate . 7 . Neurological deficit lead stupor coma ( National Institutes Health Stroke Scale ( NIHSS ) level consciousness score great equal 2 ) . 8 . High clinical suspicion septic embolus . 9 . Minor stroke nondisabling deficit rapidly improve neurological symptom . 10 . Baseline NIHSS great 18 leave hemisphere stroke great 15 others . 11 . Evidence acute chronic Intra cranial Hemorrhage ( ICH ) head CT MRI . 12 . CT MRI evidence nonvascular cause neurological symptom . 13 . Signs mass effect cause shift midline structure CT MRI . 14 . Persistent hypertension systolic BP great 185 mmHg diastolic BP great 110 mmHg control antihypertensive therapy require nitroprusside control . 15 . Blood glucose great 200 mg/dl . 16 . Anticipated need major surgery within 72 hour start study drug , e.g. , carotid endarterectomy , hip fracture repair . 17 . Any intracranial surgery , intraspinal surgery , serious head trauma ( head injury require hospitalization ) within past 3 month . 18 . Have suffer stroke within 90 day screening/baseline assessment either diagnostically confirm assumed cerebral territory current acute stroke . 19 . History ICH time past . 20 . Major trauma time stroke , e.g. , hip fracture . 21 . Presence history intracranial neoplasm ( except small meninigiomas ) arteriovenous malformation . 22 . Intracranial aneurysm , unless surgically endovascularly treat 3 month current acute stroke . 23 . Seizure onset stroke . 24 . Active internal bleeding . 25 . Major hemorrhage ( require transfusion , surgery hospitalization ) past 21 day . 26 . Major surgery , serious trauma , lumbar puncture , arterial puncture noncompressible site , biopsy parenchymal organ last 14 day . Major surgical procedure include limited following : major thoracic abdominopelvic surgery , neurosurgery , major limb surgery , carotid endarterectomy vascular surgery , organ transplantation . For nonlisted procedure , operate surgeon consult assess risk . 27 . Presumed documented history vasculitis . 28 . Known systemic bleeding platelet disorder , e.g. , von Willebrand 's disease , hemophilia , ITP , TTP , others . 29 . Platelet count less 100,000 cells/micro L. 30 . Congenital acquire coagulopathy ( e.g. , secondary anticoagulant ) . 31 . Life expectancy le 3 month . 32 . Severe renal failure . 33 . AST ALT great 3 time upper limit normal local laboratory . 34 . Any administration thrombolytic drug prior 7 day . 35 . Treatment qualify stroke intravenous heparin unless aPTT prolongation great 2 second upper limit normal local laboratory prior study drug initiation . 36 . Treatment qualify stroke low molecular weight heparin heparinoid . 37 . Known hypersensitivity tPA . 38 . Anticoagulation ( evidence abnormal INR , aPTT , platelet count ) cause herbal therapy . 39 . Ischemic change screen CT great approximately one third territory middle cerebral artery territory qualitative assessment . 40 . Female childbearing potential ( less 2 year ' postmenopausal surgically sterilize ) willing use adequate effective birth control measure duration trial . Effective birth control measure include hormonal contraception , barrier method diaphragm , intrauterine device ( IUD ) and/or condom spermicide ( IUD , diaphragm , condoms alone rhythm method consider reliable method ) . 41 . Have positive urine pregnancy test screening/baseline lactate female . 42 . Any condition investigator 's judgement preclude participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Thrombolysis</keyword>
</DOC>